FDA Approves Bayer’s Sunharbo (Asundexian), the First Factor XIa Inhibitor to Prevent Repeat Stroke
Bayer’s Sunharbo (asundexian) is the first factor XIa inhibitor approved by the FDA. It cut ischemic stroke risk by 26% in 12,327 patients after a recent stroke or high-risk TIA.